Crossmark

FDA’s Expedited Programs and Their Impact on the Availability of New Therapies

Crossref DOI link: https://doi.org/10.1177/2168479016666587

Published Online: 2017-12-31

Published Print: 2017-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Damle, Nehar

Shah, Shilvi

Nagraj, Praneeta

Tabrizi, Pardis

Rodriguez, Gustavo Enrique

Bhambri, Rahul
License Information

Text and Data Mining valid from 2017-01-01
More Information

Article History

Received: 8 June 2016

Accepted: 1 August 2016

First Online: 31 December 2017